DOI 10.1016/j.diabres.2026.113236
Association of SGLT2 inhibitors with hematologic malignancies in type 2 diabetes: a target trial emulation study.
Аннотация
AIMS: To investigate the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of hematologic malignancies compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) in patients with type 2 diabetes mellitus.
METHODS
We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2010-2025), applying a target trial emulation framework. New users of SGLT2i and DPP-4i were balanced using 1:1 propensity score matching (PSM). To ensure robustness, we calculated E-values to assess unmeasured confounding and employed landmark analyses alongside positive and negative outcome controls.
RESULTS
In a balanced cohort of 243,852 patients in each group, SGLT2i use was associated with a lower observed risk of incident hematologic malignancies compared with DPP-4i (adjusted hazard ratio [aHR] 0.90; 95% confidence interval [CI], 0.84-0.95). Subtype analyses revealed lower observed risk for leukemia (aHR 0.85; 95% CI, 0.77-0.94) and multiple myeloma (aHR 0.85; 95% CI, 0.75-0.97), while the risk for lymphoma showed a null association (aHR 0.97; 95% CI, 0.89-1.06). Validation analyses using outcome controls and E-values supported the stability of these findings.
CONCLUSIONS
SGLT2i use was associated with a lower observed risk of hematologic malignancies compared with DPP-4i, particularly leukemia and multiple myeloma. These findings warrant further investigation.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.